ANAB — AnaptysBio Cashflow Statement
0.000.00%
Last trade - 00:00- $1.79bn
- $1.76bn
- $234.60m
Annual cashflow statement for AnaptysBio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -57.8 | -129 | -164 | -145 | -13.2 |
| Depreciation | |||||
| Non-Cash Items | 18.7 | 47.6 | 42.5 | 75.6 | 113 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -7.49 | 6.84 | -0.324 | -66.3 | -80.7 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -45.9 | -73.6 | -121 | -135 | 19.7 |
| Capital Expenditures | -1.37 | -0.358 | -0.807 | -0.358 | -0.087 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 40.2 | -394 | 146 | 95.8 | 228 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 38.8 | -395 | 145 | 95.4 | 228 |
| Financing Cash Flow Items | -0.255 | 34.7 | -0.043 | 41.9 | -1.45 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 252 | 44 | -59.3 | 127 | -133 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 245 | -424 | -35.3 | 87.1 | 115 |